What effects will stopping crizotinib have on the body?

Stopping crizotinib, a targeted drug that controls tumor development by inhibiting the growth of cancer cells, may have multiple effects on the body. Once the drug is stopped, the cancer cells that were originally suppressed by the drug may start to reproduce again, which may cause the lung cancer to worsen. Recurring tumors may become more aggressive and even spread to other organs, reducing patient survival rates.

Sudden discontinuation of crizotinib after long-term use may increase the risk of cancer cells becoming resistant to the drug. This resistance is often caused by mutations in the ALK or ROS-1 proteins, which may make future treatments less effective.

While you are taking crizotinib, the drug may help maintain your electrolyte balance. However, abnormalities in electrolytes such as potassium ions and calcium ions may occur after stopping the drug. These abnormalities may cause irregular heartbeats, increase or decrease in blood pressure, and affect the patient's health.

After discontinuing crizotinib, some patients may experience visual changes, such as diplopia and blurred vision. Although these symptoms usually occur at the beginning of treatment and are more pronounced at higher doses, they may also occur or persist after discontinuation of treatment.

The gastrointestinal side effects of crizotinib, such as indigestion, nausea, vomiting, etc., may gradually lessen after stopping the drug, but some discomfort may also occur due to the sudden changes in the body's adaptation to the drug.

In addition to the above direct effects, discontinuation of crizotinib may also have an impact on the patient's psychological state, quality of life, and subsequent treatment options. For example, the deterioration of the condition may lead to patients' depression and decreased quality of life, and may also require adjustments to subsequent treatment strategies.